2023 Tuberculosis Drug Discovery and Development Gordon Research Conference and Gordon Research Seminar
2023 Tuberculosis Drug Discovery and Development Gordon Research Conference and Gordon Research Seminar
批准号:
10675238
负责人:
Dirk Schnappinger
金额:
$0.6万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-07-11 至 2023-11-30
关键词:
AddressArchitectureAreaAutomobile DrivingBacterial InfectionsBiologyBudgetsCOVID-19Cessation of lifeChemicalsClinicalClinical TrialsClinical Trials DesignCollaborationsCommunicable DiseasesCommunitiesComplexCountryCoupledDataDevelopmentDisclosureDiseaseDrug CombinationsDrug IndustryDrug resistanceDrug resistance in tuberculosisEnvironmentEvaluationFaceFacultyFosteringFunding AgencyGeographyGoalsGrowthHealth PrioritiesHourHumanIncomeIndustrializationInfectious AgentInjectableInstitutionInternationalLeadLearningLeisuresLocationMentorsMethodsMultidrug-Resistant TuberculosisMycobacterium tuberculosisOralParticipantPerformancePharmaceutical PreparationsPharmacologic SubstancePlayPostdoctoral FellowPrivatizationRegimenResearchResearch PersonnelScienceScientistSeriesSiteSocializationSpainSpeedStructureStudentsTechnologyTimeTrainingTranslational ResearchTuberculosisUnderrepresented MinorityUnited States National Institutes of HealthWomancareercareer developmentdesigndrug developmentdrug discoverydrug efficacydrug-sensitiveearly-career facultyfightingglobal healthimprovedinnovationinsightmeetingsnew technologynext generationnovelnovel strategiesnovel therapeuticspandemic diseaseprematurepreventprogramsresearch studyside effectsuccesssymposiumtuberculosis chemotherapytuberculosis drugstuberculosis treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
This application seeks support for the 2023 Tuberculosis (TB) Drug Discovery & Development Gordon Research
Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in
Castelldefels, Spain from July 22-23 and July 23 – 28, 2023. This will be the eleventh GRC on TB Drug discovery
(with the first being held in 2001 and thereafter on a biennial basis) and the fifth GRS associated with this GRC.
For more than 20 years this conference series has held a unique place in the global portfolio of TB research
conferences. For many years it has been oversubscribed, been rated above average by more than 70% of
attendees and received a high-performance rating in the GRC Evaluation. Among the factors that makes this
conference series stand out are its rigorous focus on TB drug development, the emphasis on presentation of
unpublished data (enabled by the strictly enforced rules against recording or photographing of presentations),
the disclosure of novel hit and lead compounds, the large fraction of attendees from the pharmaceutical industry,
and the well-attended networking sessions.
The overall theme for this GRC is “Leads, technologies and clinical trials for new TB drug regimens”. The
conference will discuss and disclose recently developed lead molecules as well as new technologies and
approaches to clinical trials, debate how recent insight into TB biology and performance of clinical drug
combinations may facilitate identifying leads and improving regimens, review how new technologies and trial
innovations can identify improved drug regimens, and discuss how to capitalize on successes in other disease
areas. The focus of this conference is thus quite different from the most recent conference in this series, which
centered around treatment shortening and was held in 2019.
The GRC and associated GRS foster an environment wherein which researchers are encouraged to share
cutting edge unpublished data and exchange ideas between both established and young investigators and
trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an
optional gathering for all meeting participants to address the challenges underrepresented minorities and women
face in science and to support their professional growth. Both the GRC and the GRS programs will reflect the
diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities,
and international scientists. GRCs are unique in facilitating multiple opportunities for informal interactions
between researchers from different sectors, geographies, and career stages, often resulting in exchanges
leading to new collaborations. In this pandemic era, such opportunities have become rare and thus even more
important to driving forward innovation in research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
-
批准号:10426180
-
项目类别:
-
资助金额:$29.28万
-
财政年份:2020
-
负责人:Dirk Schnappinger
-
依托单位:
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
-
批准号:10190814
-
项目类别:
-
资助金额:$30.05万
-
财政年份:2020
-
负责人:Dirk Schnappinger
-
依托单位:
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
-
批准号:10641879
-
项目类别:
-
资助金额:$28.77万
-
财政年份:2020
-
负责人:Dirk Schnappinger
-
依托单位:
Robust Genetic Switches for Mycobacteria
-
批准号:8270646
-
项目类别:
-
资助金额:$56.19万
-
财政年份:2011
-
负责人:Dirk Schnappinger
-
依托单位:
Biotin synthesis and biotin ligation in Mtb
-
批准号:8023571
-
项目类别:
-
资助金额:$63.02万
-
财政年份:2010
-
负责人:Dirk Schnappinger
-
依托单位:
Biotin synthesis and biotin ligation in Mtb
-
批准号:8204466
-
项目类别:
-
资助金额:$60.55万
-
财政年份:2010
-
负责人:Dirk Schnappinger
-
依托单位:
Biotin synthesis and biotin ligation in Mtb
-
批准号:8414837
-
项目类别:
-
资助金额:$56.92万
-
财政年份:2010
-
负责人:Dirk Schnappinger
-
依托单位:
Biotin synthesis and biotin ligation in Mtb
-
批准号:8586248
-
项目类别:
-
资助金额:$60.55万
-
财政年份:2010
-
负责人:Dirk Schnappinger
-
依托单位:
Alternative Respiratory Chains of M. tuberculosis
-
批准号:7187436
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2004
-
负责人:Dirk Schnappinger
-
依托单位:
Alternative Respiratory Chains of M. tuberculosis
-
批准号:6846083
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2004
-
负责人:Dirk Schnappinger
-
依托单位:
Alternative Respiratory Chains of M. tuberculosis
-
批准号:7009319
-
项目类别:
-
资助金额:$33.1万
-
财政年份:2004
-
负责人:Dirk Schnappinger
-
依托单位:
Alternative Respiratory Chains of M. tuberculosis
-
批准号:6703203
-
项目类别:
-
资助金额:$38.9万
-
财政年份:2004
-
负责人:Dirk Schnappinger
-
依托单位:
Project 2. Acquisition, synthesis and importance of biotin in Mtb.
-
批准号:10024705
-
项目类别:
-
资助金额:$30.48万
-
财政年份:--
-
负责人:Dirk Schnappinger
-
依托单位:
海外基金